We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+4.44%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$459M
AUM Growth
-$44.7M
(-8.9%)
Cap. Flow
-$55.5M
Cap. Flow
% of AUM
-12.09%
Top 10 Holdings %
Top 10 Hldgs %
60.52%
Holding
51
New
14
Increased
5
Reduced
22
Closed
10
Top Buys
| 1 |
Eli Lilly
LLY
|
+$45.3M |
| 2 |
Sanofi
SNY
|
+$45.2M |
| 3 |
Abbott
ABT
|
+$31M |
| 4 |
Biogen
BIIB
|
+$26.8M |
| 5 |
Centene
CNC
|
+$10.9M |
Top Sells
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$83.5M |
| 2 |
AGN
Allergan plc
AGN
|
+$38.5M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$29.9M |
| 4 |
Amgen
AMGN
|
+$17.6M |
| 5 |
Travere Therapeutics
TVTX
|
+$12.7M |
Sector Composition
| 1 | Healthcare | 90.06% |
| 2 | Financials | 4.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.05T
| $47.4M | 10.33% |
+601,800
| New | +$45.3M |
|
|
2
Sanofi
SNY
$107B
| $46.2M | 10.06% |
+1,103,300
| New | +$45.2M |
|
|
3
Abbott
ABT
$175B
| $30.6M | 6.67% |
+778,900
| New | +$31M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $30M | 6.55% |
163,200
+42,500
| +35% | +$7.67M |
|
|
5
Biogen
BIIB
$30.4B
| $24.6M | 5.35% |
+101,600
| New | +$26.8M |
|
|
6
Amgen
AMGN
$198B
| $23.7M | 5.17% |
155,932
-113,368
| -42% | -$17.6M |
|
|
TVTY
7
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $21.1M | 4.6% |
1,827,829
-393,652
| -18% | -$4.61M |
|
|
AET
8
DELISTED
Aetna Inc
AET
| $19.9M | 4.33% |
162,700
-37,300
| -19% | -$4.28M |
|
9
Elevance Health
ELV
$80.9B
| $18.9M | 4.12% |
143,800
-60,900
| -30% | -$8.33M |
|
10
Universal Health Services
UHS
$9.15B
| $15.4M | 3.35% |
114,700
+25,200
| +28% | +$3.32M |
|
|
11
Centene
CNC
$32.8B
| $12.3M | 2.69% |
+345,600
| New | +$10.9M |
|
12
Labcorp
LH
$23.2B
| $11.3M | 2.46% |
101,035
-46,560
| -32% | -$5.01M |
|
13
Enanta Pharmaceuticals
ENTA
$400M
| $10.6M | 2.32% |
482,000
+143,149
| +42% | +$3.75M |
|
|
ELGX
14
DELISTED
Endologix Inc
ELGX
| $10.1M | 2.2% |
+80,980
| New | +$9.31M |
|
|
ACOR
15
DELISTED
Acorda Therapeutics
ACOR
| $9.14M | 1.99% |
2,985
+1,444
| +94% | +$4.7M |
|
|
CNCE
16
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $8.99M | 1.96% |
800,788
-670,905
| -46% | -$8.54M |
|
|
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $8.73M | 1.9% |
808,198
-391,693
| -33% | -$4.04M |
|
|
ALDR
18
DELISTED
Alder Biopharmaceuticals
ALDR
| $8.47M | 1.84% |
339,070
-174,500
| -34% | -$4.72M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $7.93M | 1.73% |
+94,300
| New | +$4.2M |
|
20
Insmed
INSM
$23.5B
| $7.78M | 1.69% |
788,936
-316,062
| -29% | -$3.69M |
|
21
Molina Healthcare
MOH
$11.7B
| $7.52M | 1.64% |
+150,700
| New | +$8.05M |
|
22
Halozyme
HALO
$9.23B
| $6.78M | 1.48% |
+785,744
| New | +$7.75M |
|
|
CORI
23
DELISTED
Corium International, Inc.
CORI
| $6.03M | 1.31% |
1,736,466
+500
| +0% | +$2.04K |
|
|
24
Travere Therapeutics
TVTX
$5.27B
| $5.87M | 1.28% |
329,489
-785,103
| -70% | -$12.7M |
|
25
Acadia Healthcare
ACHC
$3.17B
| $5.67M | 1.24% |
+102,400
| New | +$5.99M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Senzar Asset Management held 51 positions worth $459M, down 8.9% from $504M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Senzar Asset Management withdrew a net $55.5M in Q2 2016, closing 10 positions and reducing 22 holdings. Its most notable exit was NEVRO CORP., an estimated $83.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in Eli Lilly worth $47.4M.
- Senzar Asset Management's largest Q2 2016 buy was Eli Lilly: 601,800 shares worth $47.4M.
- Senzar Asset Management added most to Shire pic in Q2 2016, an estimated $7.67M increase.
- Senzar Asset Management's biggest Q2 2016 reduction was Amgen, cutting an estimated $17.6M.
- Senzar Asset Management fully exited NEVRO CORP. in Q2 2016, selling an estimated $83.5M.
- Senzar Asset Management's ten largest holdings make up 61% of its $459M portfolio in Q2 2016.
- Senzar Asset Management opened 14 new positions and closed 10 in Q2 2016.
- Senzar Asset Management's portfolio value fell 8.9% quarter-over-quarter to $459M.
Based on Senzar Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.